Hepion Pharmaceuticals Inc (NASDAQ:HEPA)’s traded shares stood at 4.36 million during the last session, with the company’s beta value hitting 1.59. At the close of trading, the stock’s price was $0.16, to imply a decrease of -4.56% or -$0.01 in intraday trading. The HEPA share’s 52-week high remains $3.49, putting it -2081.25% down since that peak but still an impressive 25.0% since price per share fell to its 52-week low of $0.12. The company has a valuation of $1.74M, with an average of 102.85 million shares in intraday trading volume over the past 10 days and average of 16.94 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Hepion Pharmaceuticals Inc (HEPA), translating to a mean rating of 3.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give HEPA a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.
Hepion Pharmaceuticals Inc (NASDAQ:HEPA) trade information
After registering a -4.56% downside in the last session, Hepion Pharmaceuticals Inc (HEPA) has traded red over the past five days. The 5-day price performance for the stock is -7.68%, and -74.35% over 30 days. With these gigs, the year-to-date price performance is -65.24%. Short interest in Hepion Pharmaceuticals Inc (NASDAQ:HEPA) saw shorts transact 65726.0 shares and set a 0.92 days time to cover.
The extremes give us $70 and $70 for target low and target high price respectively. As such, HEPA has been trading -43650.0% off suggested target high and -43650.0% from its likely low.
HEPA Dividends
Hepion Pharmaceuticals Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Hepion Pharmaceuticals Inc (NASDAQ:HEPA)’s Major holders
Hepion Pharmaceuticals Inc insiders hold 0.08% of total outstanding shares, with institutional holders owning 7.85% of the shares at 7.85% float percentage. In total, 7.85% institutions holds shares in the company.
We also have Vanguard Extended Market Index Fund and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Hepion Pharmaceuticals Inc (HEPA) shares. Going by data provided on Sep 30, 2024 , Vanguard Extended Market Index Fund holds roughly 48.91 shares. This is just over 0.70% of the total shares, with a market valuation of $7991.0. Data from the same date shows that the other fund manager holds a little less at 40.67, or 0.58% of the shares, all valued at about 6645.0.
